ENvue Medical Stock Price, News & Analysis
Company Description
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company that focuses on non-invasive and minimally invasive systems used across clinical and home care settings. According to company disclosures, ENvue specializes in the advancement of intelligent, non-invasive solutions for enteral care, as well as non-opioid pain management and other therapeutic applications. The company is headquartered in Tyler, Texas, with research and development activities in Tel-Aviv and Nesher, Israel.
ENvue’s business centers on two primary technology platforms: an electromagnetic navigation platform for feeding-tube placement and a set of acoustic-based therapeutic devices. These platforms are intended to support patient care in hospitals, other clinical environments, and home settings.
ENvue Navigation Platform
The ENvue™ Navigation Platform, developed and operated by ENvue Medical entities with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is described as a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. The system is FDA 510(k) cleared for adult use and is designed to provide real-time bedside visualization of tube movement, supporting informed decision-making during the placement procedure.
Company materials indicate that the ENvue platform is part of a broader effort to improve standards in enteral care. The technology is positioned to support accurate feeding-tube placement and to contribute to workflow and decision support for clinicians. Disclosures also reference potential future platform expansion that may include pediatric and vascular access applications, while noting that such expansion would be subject to appropriate development and regulatory processes.
Enteral Care and ENFit Syringes
ENvue describes itself as specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. In line with this focus, the company has announced a line of over-the-counter ENFit syringes intended to support both feeding and medication delivery needs. According to ENvue, these syringes are designed for use without a prescription and are anticipated to be available through certain online retailers and durable medical equipment suppliers.
The ENFit syringes are described as meeting ISO 80369-3 global standards and being designed for reuse for up to a defined number of days or uses, with the stated goal of supporting safe and consistent enteral delivery in both clinical and home care environments. The company presents this product line as part of its effort to support continuity of care as treatment increasingly extends beyond the hospital setting.
Acoustic-Based Therapeutic Technologies
ENvue also focuses on acoustic-based therapeutic technologies, including PainShield® and UroShield®. Company descriptions state that these devices utilize proprietary low-intensity surface acoustic wave (SAW) technology. They are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
These acoustic-based systems are presented as non-invasive therapeutic options that can be applied in various care environments. ENvue positions them as complementary to its enteral access and navigation technologies, reflecting a broader focus on non-invasive therapy and patient comfort.
Focus on Patient Experience and Enteral Ecosystem
In addition to tube placement accuracy, ENvue highlights an interest in the overall enteral care experience. The company has announced a development and integration program that leverages vibration-based technology from its NanoVibronix division to address pain and discomfort associated with indwelling nasogastric (NG) tubes.
According to ENvue, this program builds on previously published, peer-reviewed clinical research indicating that surface acoustic wave micro-vibration technology applied to nasogastric tubes can reduce friction at the tube–tissue interface during indwelling use. The initiative is described as exploratory and focused on technical feasibility, clinical pathway assessment, and regulatory and quality considerations to determine how comfort-focused vibration technology could be incorporated into ENvue’s broader enteral ecosystem.
Company commentary links this work to a strategy of extending the ENvue platform beyond placement accuracy to address aspects of patient comfort, workflow efficiency, and overall enteral care, while emphasizing capital discipline and the use of technology already owned by the company.
Non-Invasive and Minimally Invasive Therapeutic Systems
Across its disclosures, ENvue characterizes itself as a medical technology company advancing non-invasive and minimally invasive solutions in both clinical and home care settings. This includes enteral access solutions, such as the ENvue Navigation Platform and ENFit syringes, as well as non-opioid pain management and other therapeutic applications enabled by surface acoustic wave technology.
The company emphasizes themes of patient safety, clinical usability, and technology innovation in describing its approach to product development and platform expansion. Its technologies are intended to support clinicians in hospitals and other care environments while also enabling treatment and symptom management in home settings.
Geographic Footprint
ENvue states that it is headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel. The ENvue Navigation Platform is described as being developed and operated by ENvue Medical entities with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel. These locations reflect the company’s combination of U.S.-based operations and Israel-based research and development capabilities.
Stock Information and Sector
ENvue Medical, Inc. trades on the Nasdaq Stock Market under the symbol FEED. Company descriptions categorize ENvue as a medical technology company, with activities that align with enteral care, navigation systems, and acoustic-based therapeutic devices. The sector classification provided identifies the company within orthopedic, prosthetic and surgical appliances and supplies, although ENvue’s own disclosures focus specifically on enteral access, non-invasive therapy, and pain management technologies.
Company Positioning
According to statements from ENvue and its leadership, the company aims to advance standards in non-invasive therapy and minimally invasive navigation across a range of healthcare environments. It highlights a commitment to patient safety, clinical usability, and technology innovation, and describes its platform as addressing needs in feeding-tube placement, enteral delivery tools, patient comfort with indwelling tubes, and acoustic-based therapies for pain and biofilm-related concerns.
Stock Performance
ENvue Medical (FEED) stock last traded at $2.46, up 0.84% from the previous close. Over the past 12 months, the stock has lost 40.0%. At a market capitalization of $2.6M, FEED is classified as a micro-cap stock with approximately 1.1M shares outstanding.
Latest News
ENvue Medical has 8 recent news articles, with the latest published 6 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 3 with negative movement. Key topics include partnership, clinical trial. View all FEED news →
SEC Filings
ENvue Medical has filed 5 recent SEC filings, including 2 Form 3, 1 Form 4, 1 Form SCHEDULE 13G/A, 1 Form SCHEDULE 13D. The most recent filing was submitted on March 6, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FEED SEC filings →
Insider Radar
Insider buying activity at ENvue Medical over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
ENvue Medical generated $2.6M in revenue over the trailing twelve months, retaining a 59.0% gross margin, operating income reached -$3.6M (-140.0% operating margin), and net income was -$3.7M, reflecting a -144.8% net profit margin. Diluted earnings per share stood at $-13.73. The company generated -$2.5M in operating cash flow. With a current ratio of 1.22, the company maintains adequate short-term liquidity.
Upcoming Events
Short Interest History
Short interest in ENvue Medical (FEED) currently stands at 1.7 million shares, up 672.7% from the previous reporting period, representing 197.1% of the float. Over the past 12 months, short interest has increased by 7705.9%. This high level of short interest suggests significant bearish sentiment among traders.
Days to Cover History
Days to cover for ENvue Medical (FEED) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
FEED Company Profile & Sector Positioning
ENvue Medical (FEED) operates in the Medical Devices industry within the broader Orthopedic, Prosthetic & Surgical Appliances & Supplies sector and is listed on the NASDAQ.